Regeneron Shares Jump After Trump Endorses 50-600% Drug Price Cuts
Regeneron struck a deal in late April with the President to lower prices on its drugs, with Trump touting cuts variously described as 50–600%, despite those percentages being mathematically flawed. Following the announcement, Regeneron shares rose as investors weighed the potential impact on revenue and margins.
1. Deal Terms
On April 23, Regeneron reached an agreement with the federal government to lower the cost of its key pharmaceutical products. The administration will collaborate with the company to implement price cuts across its portfolio starting in the next quarter.
2. Pricing Claims Controversy
During the announcement event, the President defended price reductions he described as ranging from 500% to 600%, and alternatively 50% to 90%, a method widely noted as mathematically invalid. The administration and company did not clarify which calculation underpins the final pricing structure.
3. Share Performance
In response to the pricing deal announcement, Regeneron shares climbed in late-market trading on April 23, reflecting investor optimism about regulatory support and potential volume gains. The stock's uptick suggests market expectations of improved access to therapies could drive future sales.
4. Financial Implications
Analysts warn that steep price cuts could pressure Regeneron’s profit margins, offsetting volume growth if manufacturing costs remain constant. Investors will closely monitor upcoming quarterly results for tangible effects on revenue and earnings per share.